A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens

H. C. Jeung, S. Y. Rha, B. C. Cho, N. C. Yoo, J. K. Roh, W. J. Roh, H. C. Chung, J. B. Ahn

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

This is the first phase II study of S-1 monotherapy for patients with metastatic colorectal cancer after failure of both irinotecan- and oxaliplatin-containing regimens. The initial dose of S-1 was 35 mg m -2, administered twice daily for 14 days every 3 weeks. Treatment was repeated until the occurrence of disease progression. Twenty-eight patients were enrolled. S-1 was administered to 21 patients as third-line therapy and to the remaining seven patients as fourth-line therapy. Of 26 evaluable patients, the overall response rate was 14.3% (95% CI, 0.4-28.1), and the disease control rate was 42.9% (95% CI, 23.3-62.4). With a median follow-up period of 227 days, median time to progression and overall survival duration were 91 and 414 days, respectively. The 1-year survival rate of all patients was 60.7%. There was no grade 4 toxicity. Grade 3 haematological toxicities were documented only in two patients. In conclusion, S-1 shows potential as a salvage regimen in heavily pretreated colorectal cancer patients. The twice-daily dose of 35 mg m -2 was well tolerated and can be used in designing further combination chemotherapy.

Original languageEnglish
Pages (from-to)1637-1641
Number of pages5
JournalBritish journal of cancer
Volume95
Issue number12
DOIs
Publication statusPublished - 2006 Dec 18

Fingerprint

oxaliplatin
irinotecan
Colorectal Neoplasms
Combination Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{e050292c12a6417fb0231f45038f05d0,
title = "A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens",
abstract = "This is the first phase II study of S-1 monotherapy for patients with metastatic colorectal cancer after failure of both irinotecan- and oxaliplatin-containing regimens. The initial dose of S-1 was 35 mg m -2, administered twice daily for 14 days every 3 weeks. Treatment was repeated until the occurrence of disease progression. Twenty-eight patients were enrolled. S-1 was administered to 21 patients as third-line therapy and to the remaining seven patients as fourth-line therapy. Of 26 evaluable patients, the overall response rate was 14.3{\%} (95{\%} CI, 0.4-28.1), and the disease control rate was 42.9{\%} (95{\%} CI, 23.3-62.4). With a median follow-up period of 227 days, median time to progression and overall survival duration were 91 and 414 days, respectively. The 1-year survival rate of all patients was 60.7{\%}. There was no grade 4 toxicity. Grade 3 haematological toxicities were documented only in two patients. In conclusion, S-1 shows potential as a salvage regimen in heavily pretreated colorectal cancer patients. The twice-daily dose of 35 mg m -2 was well tolerated and can be used in designing further combination chemotherapy.",
author = "Jeung, {H. C.} and Rha, {S. Y.} and Cho, {B. C.} and Yoo, {N. C.} and Roh, {J. K.} and Roh, {W. J.} and Chung, {H. C.} and Ahn, {J. B.}",
year = "2006",
month = "12",
day = "18",
doi = "10.1038/sj.bjc.6603468",
language = "English",
volume = "95",
pages = "1637--1641",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "12",

}

A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens. / Jeung, H. C.; Rha, S. Y.; Cho, B. C.; Yoo, N. C.; Roh, J. K.; Roh, W. J.; Chung, H. C.; Ahn, J. B.

In: British journal of cancer, Vol. 95, No. 12, 18.12.2006, p. 1637-1641.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens

AU - Jeung, H. C.

AU - Rha, S. Y.

AU - Cho, B. C.

AU - Yoo, N. C.

AU - Roh, J. K.

AU - Roh, W. J.

AU - Chung, H. C.

AU - Ahn, J. B.

PY - 2006/12/18

Y1 - 2006/12/18

N2 - This is the first phase II study of S-1 monotherapy for patients with metastatic colorectal cancer after failure of both irinotecan- and oxaliplatin-containing regimens. The initial dose of S-1 was 35 mg m -2, administered twice daily for 14 days every 3 weeks. Treatment was repeated until the occurrence of disease progression. Twenty-eight patients were enrolled. S-1 was administered to 21 patients as third-line therapy and to the remaining seven patients as fourth-line therapy. Of 26 evaluable patients, the overall response rate was 14.3% (95% CI, 0.4-28.1), and the disease control rate was 42.9% (95% CI, 23.3-62.4). With a median follow-up period of 227 days, median time to progression and overall survival duration were 91 and 414 days, respectively. The 1-year survival rate of all patients was 60.7%. There was no grade 4 toxicity. Grade 3 haematological toxicities were documented only in two patients. In conclusion, S-1 shows potential as a salvage regimen in heavily pretreated colorectal cancer patients. The twice-daily dose of 35 mg m -2 was well tolerated and can be used in designing further combination chemotherapy.

AB - This is the first phase II study of S-1 monotherapy for patients with metastatic colorectal cancer after failure of both irinotecan- and oxaliplatin-containing regimens. The initial dose of S-1 was 35 mg m -2, administered twice daily for 14 days every 3 weeks. Treatment was repeated until the occurrence of disease progression. Twenty-eight patients were enrolled. S-1 was administered to 21 patients as third-line therapy and to the remaining seven patients as fourth-line therapy. Of 26 evaluable patients, the overall response rate was 14.3% (95% CI, 0.4-28.1), and the disease control rate was 42.9% (95% CI, 23.3-62.4). With a median follow-up period of 227 days, median time to progression and overall survival duration were 91 and 414 days, respectively. The 1-year survival rate of all patients was 60.7%. There was no grade 4 toxicity. Grade 3 haematological toxicities were documented only in two patients. In conclusion, S-1 shows potential as a salvage regimen in heavily pretreated colorectal cancer patients. The twice-daily dose of 35 mg m -2 was well tolerated and can be used in designing further combination chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=33845666953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845666953&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6603468

DO - 10.1038/sj.bjc.6603468

M3 - Article

C2 - 17106441

AN - SCOPUS:33845666953

VL - 95

SP - 1637

EP - 1641

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 12

ER -